mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders
Crossref DOI link: https://doi.org/10.1186/s13023-017-0596-2
Published Online: 2017-03-14
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Franz, David N.
Capal, Jamie K.
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
